Celltrion and Taisho partner Kaigene sold $55M in stock, SEC filing shows
A Form D filed Oct. 14 shows the Rockville, Md., autoimmune antibody developer sold nearly $55 million of a planned $73.4 million equity offering to 22 investors. Its newsroom shows no announcement of the raise.

- Amount
- $55M
- Type
- Private placement
- Company
- Kaigene
- Sector
- Biotech
- Announced
- Oct. 14, 2026
Kaigene Inc. has announced licensing deals with Celltrion and Taisho Pharmaceutical over the past year. A new filing shows it has also raised a sizable sum of private equity that does not appear in its newsroom.
The Rockville, Md., biotech sold $54,958,229 in equity in a private offering, according to a Form D filed with the Securities and Exchange Commission on Oct. 14. The filing puts the total offering at $73.35 million, leaving about $18.4 million unsold, and lists Sept. 30 as the date of first sale. Twenty-two investors had bought in, all of them accredited, and Kaigene reported no sales commissions or finder's fees.
Why it matters: Two of Kaigene's autoimmune antibody programs, KG002 and KG006, are licensed to partners Celltrion and Japan's Taisho Pharmaceutical. The filing shows the company is also building its own balance sheet, at a scale far larger than its only earlier Form D, though it does not say who the investors are.
What the filing shows, and what it doesn't
A Form D is a short notice of a private securities sale that is exempt from SEC registration. Kaigene's lists Minjae Shin, who signed as chief executive, as an executive officer and director, and Jihoon Park as an executive officer. Kyunghyun Min and Tae Heum Jeong are listed as directors. The company was incorporated in Delaware in 2021, according to the filing, and declined to disclose its revenue range.
The filing does not name the investors, a lead investor or the series of stock sold. It gives no valuation and no planned use of proceeds beyond a standard statement that officers and directors will receive only salaries, benefits and expense reimbursements from the money.
The only earlier Form D on file for Kaigene, from March 2022, reported a $1.35 million debt sale to three investors out of a planned $5 million.
The partnerships
Kaigene says its PDEG platform is designed to selectively degrade disease-causing antibodies and to dampen antibody-producing B cells. It is also developing a nanobody-based "brain shuttle" platform, called NanoBx, meant to help antibodies cross the blood-brain barrier.
Under a November 2025 agreement, Kaigene said, Celltrion obtained worldwide rights to a candidate called KG002 and rights outside Japan and Greater China to KG006, which Kaigene describes as a next-generation FcRn inhibitor and which Celltrion calls CT-P77.
On July 30, Kaigene licensed Japanese rights to KG006 to Taisho for a $5 million upfront payment. It is eligible for up to $22 million plus ¥57.5 billion, about $351 million by the company's conversion, in milestone payments, along with tiered royalties. Kaigene said Taisho is expected to join a planned multi-regional Phase 3 trial that Celltrion will lead.
In August, Asimov said it would develop a high-yield cell line for a Kaigene multispecific antibody designed to degrade disease-causing antibodies.
What to watch
The remaining $18.4 million in the offering, and whether Kaigene ever names the investors behind the $55 million, are the open questions.



